3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Carcinoma
2
ALK-positive Advanced NSCLC
2
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Brain Neoplasms
1
Adenocarcinoma
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Cisplatin
27
Cetuximab
17
Radiotherapy
14
Carboplatin
14
pembrolizumab
11
Paclitaxel
11
Drug Therapy
8
Radiotherapy, Intensity-Modulated
7
Nivolumab
7
Fluorouracil
7
Erlotinib Hydrochloride
7
Radiation
6
Docetaxel
5
130-nm albumin-bound paclitaxel
5
Panitumumab
4
Chemoradiotherapy
3
Capecitabine
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Afatinib
3
selinexor
2
figitumumab
2
Restraint, Physical
2
Radiosurgery
2
Methotrexate
2
Lapatinib
2
Everolimus
2
Esophagectomy
2
Cyclophosphamide
2
zalutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Squamous Cell
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA